OF THE
TIMES
The existing FDA provisions also include prohibitions on providing false or misleading information to the Minister, obligations on the part of holders of a clinical trial authorization to publish prescribed information concerning clinical trials, and obligations on the part of health care institutions to provide prescribed information to the Minister about serious adverse drug reactions or medical device incidents.It may all sound reasonable on the surface, and yet within the backdrop of what
Comment: See also: